These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 17473660)

  • 1. Phase II study of gemcitabine and cisplatin in patients with previously untreated extensive stage small cell lung cancer: Southwest Oncology Group Study 9718.
    Hesketh PJ; Chansky K; Israel V; Grapski RT; Mekhail TM; Spiridonidis CH; Mills GM; Kelly K; Crowley JJ; Gandara DR
    J Thorac Oncol; 2007 May; 2(5):440-4. PubMed ID: 17473660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I/II trial of gemcitabine plus cisplatin and etoposide in patients with small-cell lung cancer.
    De Marinis F; Migliorino MR; Paoluzzi L; Portalone L; Ariganello O; Cortesi E; Gamucci T; Gasperoni S; Cipri A; Martelli O; Nelli F;
    Lung Cancer; 2003 Mar; 39(3):331-8. PubMed ID: 12609572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cisplatin-etoposide alternating with topotecan in patients with extensive stage small cell lung cancer (SCLC). A multicenter phase II study.
    Mavroudis D; Veslemes M; Kouroussis Ch; Tzanakis N; Ferdoutsis E; Toumbis M; Ziotopoulos P; Agelidou M; Tselepatiotis E; Kalbakis K; Souglakos J; Magkanas E; Samonis G; Georgoulias V;
    Lung Cancer; 2002 Oct; 38(1):59-63. PubMed ID: 12367794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paclitaxel, cisplatin, and gemcitabine combination chemotherapy within a multidisciplinary therapeutic approach in metastatic nonsmall cell lung carcinoma.
    Rodriguez J; Cortes J; Calvo E; Azinovic I; Fernandez-Hildago O; Martinez-Monge R; Garzon C; de Irala J; Martinez-Aguillo M; Ramon Y Cajal T; Brugarolas A
    Cancer; 2000 Dec; 89(12):2622-9. PubMed ID: 11135224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cisplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in untreated patients with extensive-stage small cell lung cancer: a phase II trial of the Southwest Oncology Group.
    Kelly K; Lovato L; Bunn PA; Livingston RB; Zangmeister J; Taylor SA; Roychowdhury D; Crowley JJ; Gandara DR;
    Clin Cancer Res; 2001 Aug; 7(8):2325-9. PubMed ID: 11489808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial assessing the combination of gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC).
    Antón A; Díaz-Fernández N; González Larriba JL; Vadell C; Masutti B; Montalar J; Barneto I; Artal A; Rosell R
    Lung Cancer; 1998 Nov; 22(2):139-48. PubMed ID: 10022221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of cisplatin/etoposide and endostar for extensive-stage small-cell lung cancer.
    Zhou ZT; Zhou FX; Wei Q; Zou LY; Qin BF; Peng XS
    Cancer Chemother Pharmacol; 2011 Oct; 68(4):1027-32. PubMed ID: 21327933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of paclitaxel, carboplatin, and topotecan with G-CSF support in previously untreated patients with extensive stage small cell lung cancer: Southwest Oncology Group 9914.
    Hesketh PJ; McCoy J; Dunphy FR; Bearden JD; Weiss GR; Giguere JK; Atkins JN; Dakhil SR; Kelly K; Crowley JJ; Gandara DR
    J Thorac Oncol; 2006 Nov; 1(9):991-5. PubMed ID: 17409984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An out-patient second-line chemotherapy with gemcitabine and vinorelbine in patients with non-small cell lung cancer previously treated with cisplatin-based chemotherapy. A phase II study of the Hellenic co-operative Oncology Group.
    Pectasides D; Kalofonos HP; Samantas E; Nicolaides C; Papacostas P; Onyenadum A; Visvikis A; Skarlos D; Fountzilas G
    Anticancer Res; 2001; 21(4B):3005-10. PubMed ID: 11712802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer.
    Mavroudis D; Papadakis E; Veslemes M; Tsiafaki X; Stavrakakis J; Kouroussis C; Kakolyris S; Bania E; Jordanoglou J; Agelidou M; Vlachonicolis J; Georgoulias V;
    Ann Oncol; 2001 Apr; 12(4):463-70. PubMed ID: 11398877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial.
    Zatloukal P; Petruzelka L; Zemanová M; Kolek V; Skricková J; Pesek M; Fojtů H; Grygárková I; Sixtová D; Roubec J; Horenková E; Havel L; Průsa P; Nováková L; Skácel T; Kůta M
    Lung Cancer; 2003 Sep; 41(3):321-31. PubMed ID: 12928123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cisplatin, gemcitabine, and paclitaxel in locally advanced or metastatic non-small-cell lung cancer: a phase I-II study. Southern Italy Cooperative Oncology Group.
    Frasci G; Panza N; Comella P; Nicolella GP; Natale M; Manzione L; Bilancia D; Cioffi R; Maiorino L; De Cataldis G; Belli M; Micillo E; Mascia V; Massidda B; Lorusso V; De Lena M; Carpagnano F; Contu A; Pusceddu G; Comella G
    J Clin Oncol; 1999 Aug; 17(8):2316-25. PubMed ID: 10561293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized study comparing two different schedules of administration of cisplatin in combination with gemcitabine in advanced nonsmall cell lung carcinoma.
    Ricci S; Antonuzzo A; Galli L; Tibaldi C; Bertuccelli M; Lopes Pegna A; Petruzzelli S; Bonifazi V; Orlandini C; Franco Conte P
    Cancer; 2000 Oct; 89(8):1714-9. PubMed ID: 11042565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Weekly combination chemotherapy with docetaxel and gemcitabine as first-line treatment for elderly patients and patients with poor performance status who have extensive-stage small cell lung carcinoma: a Minnie Pearl Cancer Research Network phase II trial.
    Hainsworth JD; Carrell D; Drengler RL; Scroggin C; Greco FA
    Cancer; 2004 Jun; 100(11):2437-41. PubMed ID: 15160349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Docetaxel/gemcitabine or cisplatin/gemcitabine followed by docetaxel in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC): results of a multicentre randomized phase II trial.
    Binder D; Schweisfurth H; Grah C; Schäper C; Temmesfeld-Wollbrück B; Siebert G; Suttorp N; Beinert T
    Cancer Chemother Pharmacol; 2007 Jun; 60(1):143-50. PubMed ID: 17031643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicenter, randomized, Phase II study of cisplatin, etoposide, and gemcitabine or cisplatin plus gemcitabine as first-line treatment in patients with poor-prognosis small cell lung carcinoma.
    De Marinis F; Nelli F; Lombardo M; Ferraú F; Barbera S; Bertetto O; Barni S; Michetti G; Labianca R; Gridelli C
    Cancer; 2005 Feb; 103(4):772-9. PubMed ID: 15641037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gemcitabine in brief versus prolonged low-dose infusion, both combined with cisplatin, for advanced non-small cell lung cancer: a randomized phase II clinical trial.
    Zwitter M; Kovac V; Smrdel U; Vrankar M; Zadnik V
    J Thorac Oncol; 2009 Sep; 4(9):1148-55. PubMed ID: 19546818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreased myelotoxicity of gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC) with cisplatin infusion on day 15.
    Cortesi E; Ramponi S; Corona M; Moscetti L; Grifalchi F; Oliva A; Lembo A; Gasperoni S; Padovani A
    Lung Cancer; 2001; 31(2-3):271-6. PubMed ID: 11165407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective phase II trial of a combination of fixed dose rate infusion of gemcitabine with cisplatin and UFT as a first-line treatment in patients with advanced non-small-cell lung carcinoma.
    Shin SJ; Kim H; Baek JH; Ahn JJ; Jegal Y; Seo KW; Park CR; Shin JK; Jung JP; Kim JW; Cha HJ; Kwon WJ; Jeong AK; Noh YJ; Park JH; Min YJ
    Lung Cancer; 2008 Apr; 60(1):83-91. PubMed ID: 18006180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of low-dose gemcitabine in prolonged infusion and cisplatin for advanced non-small cell lung cancer.
    Xiong JP; Feng M; Qiu F; Xu J; Tao QS; Zhang L; Xiang XJ; Zhong LX; Yu F; Ma XT; Gong WY
    Lung Cancer; 2008 May; 60(2):208-14. PubMed ID: 18023915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.